| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 82 | 2024 | 5061 | 7.900 |
Why?
|
| Pancreatectomy | 36 | 2024 | 652 | 7.780 |
Why?
|
| Pancreaticoduodenectomy | 34 | 2023 | 690 | 6.870 |
Why?
|
| Hepatectomy | 68 | 2023 | 1011 | 6.860 |
Why?
|
| Carcinoma, Pancreatic Ductal | 40 | 2024 | 1724 | 6.600 |
Why?
|
| Adenocarcinoma | 48 | 2024 | 7789 | 4.900 |
Why?
|
| Analgesics, Opioid | 20 | 2023 | 1371 | 4.590 |
Why?
|
| Liver Neoplasms | 68 | 2024 | 4557 | 4.340 |
Why?
|
| Pain, Postoperative | 16 | 2023 | 610 | 4.150 |
Why?
|
| Colorectal Neoplasms | 46 | 2024 | 3578 | 3.430 |
Why?
|
| Practice Patterns, Physicians' | 13 | 2022 | 1303 | 3.340 |
Why?
|
| Drug Prescriptions | 8 | 2022 | 289 | 3.020 |
Why?
|
| Surgical Oncology | 7 | 2020 | 190 | 2.910 |
Why?
|
| Portal Vein | 13 | 2021 | 355 | 2.670 |
Why?
|
| Neoadjuvant Therapy | 47 | 2024 | 4975 | 2.550 |
Why?
|
| Pancreatic Fistula | 11 | 2023 | 99 | 2.370 |
Why?
|
| Postoperative Complications | 32 | 2023 | 5542 | 2.360 |
Why?
|
| Venous Thromboembolism | 6 | 2022 | 335 | 1.900 |
Why?
|
| Retrospective Studies | 113 | 2024 | 37905 | 1.780 |
Why?
|
| Patient Discharge | 8 | 2023 | 661 | 1.750 |
Why?
|
| Cholangiocarcinoma | 13 | 2024 | 493 | 1.720 |
Why?
|
| Bile Duct Neoplasms | 13 | 2024 | 493 | 1.720 |
Why?
|
| Gallbladder Neoplasms | 9 | 2023 | 245 | 1.690 |
Why?
|
| Amylases | 2 | 2023 | 66 | 1.650 |
Why?
|
| Blood Transfusion | 8 | 2021 | 583 | 1.640 |
Why?
|
| Gastric Bypass | 2 | 2022 | 81 | 1.510 |
Why?
|
| Humans | 238 | 2024 | 261506 | 1.480 |
Why?
|
| Robotic Surgical Procedures | 11 | 2023 | 481 | 1.470 |
Why?
|
| Perioperative Care | 6 | 2022 | 451 | 1.400 |
Why?
|
| Aged | 109 | 2023 | 70117 | 1.350 |
Why?
|
| Prognosis | 67 | 2024 | 21713 | 1.300 |
Why?
|
| CA-19-9 Antigen | 8 | 2024 | 144 | 1.290 |
Why?
|
| Middle Aged | 111 | 2024 | 86204 | 1.240 |
Why?
|
| Aged, 80 and over | 60 | 2023 | 29902 | 1.190 |
Why?
|
| Gastrectomy | 7 | 2023 | 451 | 1.180 |
Why?
|
| Mesenteric Veins | 5 | 2020 | 73 | 1.180 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 10035 | 1.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 15862 | 1.160 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2019 | 262 | 1.160 |
Why?
|
| Laparoscopy | 12 | 2023 | 1225 | 1.130 |
Why?
|
| Survival Rate | 52 | 2023 | 12221 | 1.130 |
Why?
|
| Quality Improvement | 4 | 2020 | 851 | 1.130 |
Why?
|
| Male | 120 | 2024 | 123000 | 1.080 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2021 | 607 | 1.040 |
Why?
|
| Critical Pathways | 7 | 2024 | 149 | 1.030 |
Why?
|
| Inpatients | 5 | 2022 | 678 | 1.030 |
Why?
|
| Cholecystectomy | 5 | 2021 | 107 | 1.020 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 384 | 1.020 |
Why?
|
| Female | 122 | 2024 | 141928 | 1.010 |
Why?
|
| Embolization, Therapeutic | 7 | 2021 | 551 | 1.010 |
Why?
|
| Surgeons | 3 | 2021 | 519 | 0.970 |
Why?
|
| Methocarbamol | 1 | 2023 | 2 | 0.960 |
Why?
|
| Postoperative Hemorrhage | 4 | 2018 | 162 | 0.960 |
Why?
|
| Fibrinolytic Agents | 3 | 2016 | 324 | 0.940 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 651 | 0.940 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 715 | 0.930 |
Why?
|
| Chemotherapy, Adjuvant | 20 | 2023 | 3890 | 0.910 |
Why?
|
| Habits | 2 | 2020 | 36 | 0.910 |
Why?
|
| Preoperative Care | 10 | 2021 | 1529 | 0.900 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 394 | 0.890 |
Why?
|
| Adult | 78 | 2023 | 77950 | 0.890 |
Why?
|
| Liver | 8 | 2020 | 2961 | 0.880 |
Why?
|
| Colectomy | 3 | 2017 | 288 | 0.870 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 14889 | 0.860 |
Why?
|
| Lymph Node Excision | 8 | 2022 | 1959 | 0.860 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2022 | 31 | 0.830 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2022 | 59 | 0.830 |
Why?
|
| Neoplasm Staging | 31 | 2024 | 13658 | 0.820 |
Why?
|
| Blood Loss, Surgical | 4 | 2023 | 309 | 0.790 |
Why?
|
| Treatment Outcome | 50 | 2023 | 32848 | 0.770 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 2403 | 0.760 |
Why?
|
| Bile Ducts | 2 | 2018 | 113 | 0.750 |
Why?
|
| Risk Factors | 27 | 2023 | 17523 | 0.740 |
Why?
|
| Surgical Procedures, Operative | 2 | 2021 | 383 | 0.730 |
Why?
|
| Esophagectomy | 2 | 2015 | 911 | 0.730 |
Why?
|
| Neoplasms | 9 | 2024 | 15193 | 0.720 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 98 | 0.720 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2023 | 275 | 0.720 |
Why?
|
| Digestive System Neoplasms | 2 | 2020 | 82 | 0.720 |
Why?
|
| Gastroparesis | 1 | 2020 | 72 | 0.720 |
Why?
|
| Hepatic Insufficiency | 2 | 2017 | 34 | 0.720 |
Why?
|
| Patient Selection | 6 | 2020 | 2055 | 0.710 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 2027 | 0.710 |
Why?
|
| Risk Assessment | 15 | 2021 | 6869 | 0.710 |
Why?
|
| Common Bile Duct | 1 | 2019 | 27 | 0.700 |
Why?
|
| Time Factors | 22 | 2024 | 12926 | 0.690 |
Why?
|
| Intraoperative Complications | 2 | 2019 | 301 | 0.670 |
Why?
|
| Morbidity | 5 | 2015 | 397 | 0.670 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 71 | 0.660 |
Why?
|
| Prospective Studies | 17 | 2023 | 12873 | 0.650 |
Why?
|
| Deoxycytidine | 10 | 2022 | 1353 | 0.650 |
Why?
|
| Duodenal Neoplasms | 2 | 2017 | 138 | 0.640 |
Why?
|
| Fluorouracil | 12 | 2024 | 1944 | 0.610 |
Why?
|
| Vascular Patency | 1 | 2018 | 218 | 0.610 |
Why?
|
| Stomach Neoplasms | 4 | 2022 | 2278 | 0.600 |
Why?
|
| Propensity Score | 7 | 2023 | 750 | 0.600 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 524 | 0.600 |
Why?
|
| ErbB Receptors | 5 | 2011 | 2295 | 0.600 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 671 | 0.590 |
Why?
|
| Leucovorin | 9 | 2024 | 332 | 0.590 |
Why?
|
| Teratoma | 1 | 2019 | 236 | 0.590 |
Why?
|
| Texas | 11 | 2021 | 6311 | 0.590 |
Why?
|
| Sarcoma | 6 | 2020 | 1725 | 0.580 |
Why?
|
| Thrombophilia | 1 | 2016 | 56 | 0.560 |
Why?
|
| Albumins | 5 | 2022 | 258 | 0.550 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 232 | 0.550 |
Why?
|
| Vascular Surgical Procedures | 2 | 2018 | 655 | 0.540 |
Why?
|
| Thrombelastography | 1 | 2016 | 79 | 0.540 |
Why?
|
| Blood Coagulation | 1 | 2016 | 185 | 0.530 |
Why?
|
| Lymphatic Metastasis | 9 | 2021 | 4844 | 0.530 |
Why?
|
| Young Adult | 25 | 2020 | 21445 | 0.520 |
Why?
|
| Cardia | 1 | 2014 | 39 | 0.510 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 598 | 0.510 |
Why?
|
| Hepatic Veins | 3 | 2020 | 58 | 0.510 |
Why?
|
| United States | 20 | 2022 | 15433 | 0.500 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.490 |
Why?
|
| Rectal Neoplasms | 4 | 2023 | 1202 | 0.490 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 4298 | 0.490 |
Why?
|
| Biomarkers, Tumor | 14 | 2024 | 10331 | 0.470 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1130 | 0.460 |
Why?
|
| Mutation | 23 | 2023 | 15179 | 0.460 |
Why?
|
| Stents | 2 | 2023 | 1096 | 0.450 |
Why?
|
| Incidence | 10 | 2023 | 5673 | 0.450 |
Why?
|
| Proportional Hazards Models | 12 | 2023 | 4988 | 0.440 |
Why?
|
| Margins of Excision | 8 | 2022 | 285 | 0.430 |
Why?
|
| Research Design | 1 | 2020 | 1544 | 0.430 |
Why?
|
| Postoperative Care | 4 | 2021 | 739 | 0.420 |
Why?
|
| Klatskin Tumor | 2 | 2022 | 29 | 0.420 |
Why?
|
| Multidetector Computed Tomography | 2 | 2020 | 150 | 0.420 |
Why?
|
| Decision Making | 2 | 2020 | 1287 | 0.400 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 4892 | 0.400 |
Why?
|
| SEER Program | 1 | 2014 | 1000 | 0.390 |
Why?
|
| Cohort Studies | 11 | 2023 | 9244 | 0.390 |
Why?
|
| Genes, erbB-1 | 2 | 2010 | 101 | 0.390 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 3719 | 0.390 |
Why?
|
| Combined Modality Therapy | 14 | 2023 | 8865 | 0.390 |
Why?
|
| Lymph Nodes | 6 | 2023 | 2967 | 0.380 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2023 | 334 | 0.380 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2023 | 167 | 0.380 |
Why?
|
| Paclitaxel | 5 | 2022 | 1996 | 0.380 |
Why?
|
| Drainage | 2 | 2023 | 416 | 0.370 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.360 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2023 | 145 | 0.360 |
Why?
|
| Ampulla of Vater | 2 | 2023 | 155 | 0.360 |
Why?
|
| Bilirubin | 3 | 2024 | 221 | 0.360 |
Why?
|
| Catheter Ablation | 2 | 2012 | 620 | 0.350 |
Why?
|
| Neuroendocrine Tumors | 3 | 2021 | 634 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2020 | 6207 | 0.340 |
Why?
|
| Population Surveillance | 1 | 2013 | 627 | 0.340 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 235 | 0.340 |
Why?
|
| Robotics | 2 | 2023 | 359 | 0.330 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2018 | 565 | 0.320 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 1258 | 0.320 |
Why?
|
| Reoperation | 3 | 2019 | 1382 | 0.320 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 1331 | 0.310 |
Why?
|
| Smad4 Protein | 2 | 2019 | 196 | 0.300 |
Why?
|
| Perception | 2 | 2020 | 350 | 0.300 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 14289 | 0.290 |
Why?
|
| Metastasectomy | 2 | 2020 | 200 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2022 | 3552 | 0.290 |
Why?
|
| Databases, Factual | 6 | 2021 | 2218 | 0.290 |
Why?
|
| Betacoronavirus | 3 | 2020 | 527 | 0.280 |
Why?
|
| Kentucky | 2 | 2016 | 20 | 0.280 |
Why?
|
| Disease-Free Survival | 13 | 2020 | 10001 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2017 | 2231 | 0.270 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 1323 | 0.270 |
Why?
|
| Length of Stay | 5 | 2022 | 1900 | 0.270 |
Why?
|
| ras Proteins | 2 | 2020 | 770 | 0.270 |
Why?
|
| Gene Dosage | 2 | 2009 | 829 | 0.260 |
Why?
|
| Pancreas | 4 | 2023 | 718 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2021 | 2803 | 0.260 |
Why?
|
| Odds Ratio | 4 | 2013 | 2316 | 0.250 |
Why?
|
| Adolescent | 13 | 2019 | 31252 | 0.240 |
Why?
|
| Age Factors | 5 | 2018 | 5377 | 0.240 |
Why?
|
| Pain Management | 2 | 2020 | 668 | 0.240 |
Why?
|
| Cholangitis | 1 | 2024 | 48 | 0.240 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 1390 | 0.240 |
Why?
|
| Incisional Hernia | 1 | 2023 | 9 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2024 | 7551 | 0.230 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2009 | 882 | 0.230 |
Why?
|
| Biliary Tract | 1 | 2023 | 37 | 0.230 |
Why?
|
| Morphine | 2 | 2022 | 308 | 0.230 |
Why?
|
| Celecoxib | 1 | 2023 | 200 | 0.230 |
Why?
|
| Postoperative Period | 2 | 2020 | 665 | 0.230 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 15694 | 0.220 |
Why?
|
| Survival Analysis | 9 | 2021 | 9180 | 0.220 |
Why?
|
| Genes, ras | 4 | 2021 | 667 | 0.220 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2023 | 42 | 0.220 |
Why?
|
| Operative Time | 4 | 2023 | 217 | 0.220 |
Why?
|
| Hypertension, Portal | 1 | 2024 | 124 | 0.220 |
Why?
|
| Incidental Findings | 3 | 2019 | 272 | 0.220 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1960 | 0.220 |
Why?
|
| Pandemics | 3 | 2020 | 1559 | 0.220 |
Why?
|
| Acetaminophen | 1 | 2023 | 116 | 0.220 |
Why?
|
| Carbohydrates | 1 | 2022 | 68 | 0.210 |
Why?
|
| Cystic Duct | 2 | 2019 | 10 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 945 | 0.210 |
Why?
|
| Chemoradiotherapy | 5 | 2019 | 1946 | 0.210 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 821 | 0.210 |
Why?
|
| Aftercare | 1 | 2023 | 259 | 0.210 |
Why?
|
| Pancreatitis, Chronic | 1 | 2022 | 116 | 0.210 |
Why?
|
| Pancreatic Cyst | 1 | 2022 | 107 | 0.200 |
Why?
|
| Elective Surgical Procedures | 2 | 2013 | 250 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 907 | 0.200 |
Why?
|
| Device Removal | 1 | 2023 | 337 | 0.200 |
Why?
|
| Sarcopenia | 2 | 2020 | 110 | 0.200 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 68 | 0.190 |
Why?
|
| Harm Reduction | 1 | 2020 | 16 | 0.190 |
Why?
|
| Exercise Therapy | 2 | 2023 | 288 | 0.190 |
Why?
|
| Gastric Emptying | 1 | 2020 | 94 | 0.190 |
Why?
|
| Patient Readmission | 4 | 2022 | 548 | 0.190 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 158 | 0.190 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 126 | 0.180 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 42 | 0.180 |
Why?
|
| GTP Phosphohydrolases | 2 | 2019 | 336 | 0.180 |
Why?
|
| Biology | 1 | 2020 | 75 | 0.180 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 1162 | 0.180 |
Why?
|
| Hospital Costs | 2 | 2024 | 228 | 0.180 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 50 | 0.180 |
Why?
|
| Feasibility Studies | 3 | 2021 | 2292 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5319 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2020 | 87 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2020 | 1375 | 0.170 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 5687 | 0.170 |
Why?
|
| Intestinal Neoplasms | 1 | 2020 | 189 | 0.170 |
Why?
|
| Patient-Specific Modeling | 1 | 2018 | 28 | 0.170 |
Why?
|
| Cisplatin | 3 | 2023 | 2432 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 497 | 0.160 |
Why?
|
| Phlebography | 1 | 2018 | 76 | 0.160 |
Why?
|
| Disease Progression | 4 | 2019 | 6682 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.160 |
Why?
|
| Neoplasm, Residual | 3 | 2019 | 1656 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2021 | 11965 | 0.160 |
Why?
|
| Body Composition | 2 | 2020 | 595 | 0.160 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 213 | 0.160 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 313 | 0.160 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2010 | 388 | 0.160 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 11538 | 0.160 |
Why?
|
| Intraoperative Care | 1 | 2019 | 259 | 0.160 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 168 | 0.150 |
Why?
|
| Logistic Models | 3 | 2013 | 3441 | 0.150 |
Why?
|
| Splenic Vein | 1 | 2017 | 17 | 0.150 |
Why?
|
| Efficiency | 1 | 2018 | 99 | 0.150 |
Why?
|
| Hospital Mortality | 4 | 2021 | 1274 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 630 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2018 | 202 | 0.150 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 190 | 0.150 |
Why?
|
| Muscular Atrophy | 1 | 2018 | 105 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 294 | 0.150 |
Why?
|
| Splenic Artery | 1 | 2017 | 50 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Liver Failure | 1 | 2018 | 140 | 0.150 |
Why?
|
| Carcinoma in Situ | 1 | 2021 | 487 | 0.150 |
Why?
|
| Walking | 1 | 2019 | 277 | 0.150 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 122 | 0.150 |
Why?
|
| Liver Transplantation | 2 | 2016 | 1112 | 0.150 |
Why?
|
| Ipilimumab | 1 | 2022 | 710 | 0.150 |
Why?
|
| Career Mobility | 1 | 2018 | 95 | 0.150 |
Why?
|
| General Surgery | 1 | 2020 | 326 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 231 | 0.150 |
Why?
|
| Preoperative Period | 4 | 2020 | 344 | 0.150 |
Why?
|
| Palliative Care | 2 | 2022 | 2037 | 0.150 |
Why?
|
| Atrophy | 1 | 2017 | 261 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 234 | 0.140 |
Why?
|
| Liver Regeneration | 1 | 2017 | 134 | 0.140 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2009 | 297 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 560 | 0.140 |
Why?
|
| Serum Albumin | 2 | 2014 | 257 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2017 | 182 | 0.140 |
Why?
|
| Diaphragm | 1 | 2017 | 181 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5112 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 390 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 2020 | 611 | 0.140 |
Why?
|
| Thyroidectomy | 1 | 2019 | 486 | 0.140 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 223 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2019 | 1391 | 0.140 |
Why?
|
| Liposarcoma | 1 | 2017 | 214 | 0.130 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2016 | 43 | 0.130 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2015 | 34 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2020 | 1450 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 3981 | 0.130 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 436 | 0.130 |
Why?
|
| Microvessels | 1 | 2016 | 135 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2018 | 289 | 0.130 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 343 | 0.130 |
Why?
|
| Analgesia, Epidural | 1 | 2015 | 102 | 0.120 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2015 | 74 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.120 |
Why?
|
| Quinazolines | 3 | 2010 | 923 | 0.120 |
Why?
|
| Health Expenditures | 1 | 2016 | 211 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Health Policy | 1 | 2017 | 291 | 0.120 |
Why?
|
| Hypertrophy | 3 | 2020 | 162 | 0.120 |
Why?
|
| Melanoma | 2 | 2021 | 5317 | 0.120 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 45 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.120 |
Why?
|
| Hospitalization | 2 | 2024 | 2083 | 0.120 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2024 | 222 | 0.110 |
Why?
|
| Camptothecin | 2 | 2013 | 517 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 1216 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.110 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 102 | 0.110 |
Why?
|
| Emergency Treatment | 1 | 2014 | 105 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2018 | 674 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2019 | 650 | 0.110 |
Why?
|
| Office Visits | 1 | 2013 | 97 | 0.110 |
Why?
|
| Markov Chains | 1 | 2013 | 175 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2992 | 0.110 |
Why?
|
| Pain | 2 | 2023 | 1658 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 1249 | 0.110 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 14551 | 0.110 |
Why?
|
| Tumor Burden | 4 | 2021 | 1987 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 717 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 100 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2023 | 6100 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2819 | 0.100 |
Why?
|
| Algorithms | 2 | 2020 | 3890 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2012 | 193 | 0.100 |
Why?
|
| Comorbidity | 2 | 2016 | 2352 | 0.100 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 2283 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 3472 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2018 | 806 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2011 | 261 | 0.090 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 462 | 0.090 |
Why?
|
| Contrast Media | 2 | 2020 | 1472 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2011 | 8873 | 0.090 |
Why?
|
| Intestine, Small | 2 | 2020 | 499 | 0.090 |
Why?
|
| Receptor, ErbB-3 | 1 | 2010 | 122 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 4849 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 739 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3251 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 702 | 0.090 |
Why?
|
| Introns | 2 | 2010 | 432 | 0.090 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2009 | 46 | 0.090 |
Why?
|
| Duodenum | 2 | 2023 | 149 | 0.090 |
Why?
|
| Chile | 2 | 2019 | 61 | 0.090 |
Why?
|
| Radiography | 2 | 2020 | 1904 | 0.090 |
Why?
|
| Wnt1 Protein | 1 | 2009 | 103 | 0.080 |
Why?
|
| Hepatic Artery | 2 | 2022 | 240 | 0.080 |
Why?
|
| Cyclin A | 1 | 2008 | 47 | 0.080 |
Why?
|
| Giant Cell Tumors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 3842 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4367 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 992 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1866 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4638 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1443 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 622 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 231 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 584 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 761 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2014 | 977 | 0.070 |
Why?
|
| Laparotomy | 2 | 2024 | 211 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2009 | 1442 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2009 | 258 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 423 | 0.070 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2864 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2011 | 1620 | 0.070 |
Why?
|
| Motivation | 2 | 2019 | 499 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 460 | 0.070 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 941 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 1450 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4654 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 600 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2195 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2023 | 1283 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 2054 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2010 | 4757 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2011 | 1165 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 524 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 3639 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2023 | 68 | 0.060 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 14 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 629 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 310 | 0.050 |
Why?
|
| Angiography | 1 | 2024 | 360 | 0.050 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2022 | 71 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2022 | 105 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 310 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 181 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 153 | 0.050 |
Why?
|
| Organ Size | 2 | 2013 | 690 | 0.050 |
Why?
|
| Cholangiography | 1 | 2021 | 36 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5437 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 227 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 388 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 70 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 273 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 254 | 0.050 |
Why?
|
| Rectum | 1 | 2023 | 467 | 0.050 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 83 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 245 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2023 | 500 | 0.050 |
Why?
|
| Fluorescence | 1 | 2021 | 195 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2018 | 1270 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2021 | 234 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4320 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2021 | 117 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 842 | 0.050 |
Why?
|
| Perioperative Period | 1 | 2021 | 155 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2021 | 122 | 0.050 |
Why?
|
| Organoids | 1 | 2022 | 287 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 138 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 3536 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2023 | 450 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2359 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 447 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 1225 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2019 | 122 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 669 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 452 | 0.040 |
Why?
|
| Medicaid | 1 | 2021 | 279 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2010 | 7226 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2018 | 50 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 649 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 149 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2009 | 542 | 0.040 |
Why?
|
| Relative Value Scales | 1 | 2018 | 14 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1382 | 0.040 |
Why?
|
| Streptozocin | 1 | 2018 | 75 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 2173 | 0.040 |
Why?
|
| Vascular System Injuries | 1 | 2018 | 52 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 205 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2588 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2022 | 925 | 0.040 |
Why?
|
| Ligaments | 1 | 2017 | 43 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 104 | 0.040 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 108 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 122 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7548 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 490 | 0.040 |
Why?
|
| Radiographic Image Enhancement | 1 | 2020 | 402 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 95 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 521 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2018 | 132 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 7702 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 371 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2017 | 16273 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 92 | 0.040 |
Why?
|
| Anthropometry | 1 | 2017 | 269 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2011 | 1037 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 1099 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 348 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 980 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 1090 | 0.040 |
Why?
|
| Models, Economic | 1 | 2016 | 101 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2016 | 110 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1146 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 770 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 651 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2016 | 94 | 0.030 |
Why?
|
| Publishing | 1 | 2018 | 220 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 363 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 233 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2021 | 2084 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1183 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2019 | 667 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 249 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 603 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 611 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 237 | 0.030 |
Why?
|
| Glioma | 1 | 2006 | 1963 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 244 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1392 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 207 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 255 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2011 | 2450 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 2014 | 36 | 0.030 |
Why?
|
| Bile | 1 | 2013 | 81 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2013 | 246 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 692 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 348 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2018 | 831 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2016 | 233 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 2594 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 835 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2086 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Infant | 1 | 2007 | 13310 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 1062 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 226 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2291 | 0.030 |
Why?
|
| Suture Techniques | 1 | 2013 | 319 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 1052 | 0.020 |
Why?
|
| Child | 3 | 2018 | 29154 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2018 | 3005 | 0.020 |
Why?
|
| Chromones | 1 | 2010 | 120 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2011 | 323 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 2518 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 445 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 518 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Flavonoids | 1 | 2010 | 188 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2011 | 652 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 884 | 0.020 |
Why?
|
| Morpholines | 1 | 2010 | 289 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1062 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2008 | 72 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 6942 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 886 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 150 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2139 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 717 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 6295 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 690 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1869 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2006 | 256 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 1408 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 660 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2009 | 1064 | 0.020 |
Why?
|
| beta Catenin | 1 | 2009 | 688 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 34495 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1910 | 0.020 |
Why?
|
| Karyotyping | 1 | 2006 | 1022 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 3101 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 5395 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1678 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 4804 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 1471 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 3821 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 4109 | 0.010 |
Why?
|
| Biopsy | 1 | 2009 | 3443 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 6150 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 59536 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4744 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2009 | 2669 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5178 | 0.010 |
Why?
|